Precautions in Molar Pregnancy Evacuation

1. Pre-Evacuation Assessment & Stabilization

• Preeclampsia — assess blood pressure and manage hypertension
• Hyperthyroidism — check for tachycardia, warm skin, tremor; confirm with serum free T4 and T3 levels
• Electrolyte imbalance — hyperemesis may cause severe disturbances requiring IV replacement
• Anemia — assess hematologic status; blood products should be available
• Theca lutein cysts — document with ultrasound; large cysts may cause pelvic pressure or risk torsion

"When molar pregnancy is diagnosed, the patient should be evaluated for the presence of associated medical complications, including preeclampsia, hyperthyroidism, electrolyte imbalance, and anemia. After the patient's condition is stabilized, a decision must be made concerning the most appropriate method of evacuation." — Berek & Novak's Gynecology

2. Precautions Regarding Hyperthyroidism

• If hyperthyroidism is suspected before induction of anesthesia, β-adrenergic blocking agents must be administered to prevent thyroid storm
• Thyroid storm can manifest as hyperthermia, delirium, convulsions, tachycardia, high-output heart failure, or cardiovascular collapse
• A multidisciplinary approach involving anesthesia, endocrinology, and the surgical team is warranted
• After evacuation, thyroid function typically normalizes rapidly

3. Preferred Method: Suction Curettage

1. Oxytocin infusion — Begin before induction of anesthesia to enhance uterine contractility and reduce hemorrhage
2. Cervical dilation — Proceed promptly even if bleeding increases during dilation; retained blood may be expelled
3. Suction curettage — Use a 12-mm cannula. If uterus >14 weeks, place one hand on the fundus and massage continuously to stimulate contraction and reduce the risk of perforation
4. Sharp curettage — Perform gentle sharp curettage after suction to remove residual molar tissue
5. Ultrasound guidance — Perform the evacuation under ultrasound guidance when possible

4. Avoid Medical-Only (Medication) Evacuation

• Incomplete evacuation (up to 25%)
• Hemorrhage
• Infection
• Subsequent need for chemotherapy
• Trophoblastic embolization — a life-threatening complication causing respiratory failure and death

5. Trophoblastic Embolization / Respiratory Precautions

• Occurs in patients with excessively enlarged uteri and markedly elevated hCG
• Watch for: chest pain, dyspnea, tachypnea, tachycardia, bilateral pulmonary infiltrates
• Have cardiopulmonary support ready; mechanical ventilation may be required
• Respiratory distress usually resolves within 72 hours with support

6. Rh Immunoglobulin Administration

• Trophoblast cells express the RhD factor
• All Rh-negative patients must receive Rh immune globulin at the time of evacuation to prevent alloimmunization

7. Avoid Unnecessary Uterotonic Use Before Evacuation Begins

• Uterotonics should be used once evacuation has begun (not before), to aid uterine contractility without causing premature expulsion of trophoblastic tissue into the circulation

8. Post-Evacuation Monitoring (Follow-up Precautions)

• Serial serum β-hCG monitoring is mandatory to detect gestational trophoblastic neoplasia (GTN)
  • Weekly until normal for 3 consecutive weeks, then monthly for at least 6 months
• GTN occurs after ~15–20% of complete moles and 1–5% of partial moles
• Refer to gynecologic oncology if β-hCG plateaus, rises, or persists >6 months
• Theca lutein cysts regress spontaneously within 2–4 months post-evacuation

Summary Table

β-hCG Follow-Up in Suspected Gestational Trophoblastic Neoplasia (GTN)

Why β-hCG?

Post-Molar Evacuation Surveillance Protocol

Frequency of Testing

• The average time to achieve the first normal hCG after molar evacuation is approximately 9 weeks
• Once serum hCG becomes non-detectable, the risk of developing GTN approaches zero

UK Protocol (RCOG-based)

• If hCG normalizes within 56 days of evacuation → follow-up for 6 months from evacuation date
• If hCG does not normalize within 56 days → follow-up for 6 months from the date of normalization
• Patients are registered for lifetime follow-up as recurrence can occur years later
• After any future pregnancy, hCG is checked at 6–8 weeks post-pregnancy to exclude recurrence

When to Suspect / Diagnose GTN

1. Plateau of hCG over 3 or more values across ≥2 weeks
2. Rise in hCG on 3 weekly measurements over ≥2 weeks
3. Persistent elevation beyond 6 months after evacuation
4. Elevation after initial normalization (recurrence pattern)

GTN occurs in approximately 15–20% of complete moles and 1–5% of partial moles

hCG in Prognosis: FIGO/WHO Scoring

• Score < 7 → Low risk → single-agent chemotherapy
• Score ≥ 7 → High risk → multiagent combination chemotherapy

CSF hCG in Brain Metastasis

• In patients with choriocarcinoma or metastatic GTN, plasma-to-CSF hCG ratio < 60 is suggestive of cerebral metastases
• Useful when CT/MRI brain is normal but CNS involvement is suspected
• Caution: rapid changes in plasma hCG may not be immediately reflected in CSF

Phantom β-hCG (False Positive) — Important Pitfall

• Circulating heterophilic antibodies can cause false-positive serum hCG (phantom hCG syndrome)
• This may lead to inappropriate GTN treatment
• Exclude with: simultaneous urine hCG (these serum factors are NOT excreted in urine) OR serial serum dilution (true hCG dilutes linearly; false-positive does not) OR use of an alternative testing platform

Special Situations

Twin pregnancy (normal + molar gestation)

• Rate of persistent GTN requiring chemotherapy is no different from singleton molar pregnancy, regardless of whether the pregnancy is terminated
• β-hCG surveillance follows the same protocol post-delivery or termination

Non-molar antecedent pregnancy

• GTN arising after term delivery or non-molar abortion always has the histologic pattern of choriocarcinoma
• Surveillance is the same; referral to gynecologic oncology is mandatory

Contraception during follow-up

• Oral contraceptives are safe throughout the surveillance period — they do not increase risk of persistent GTN
• Intrauterine devices should be avoided until hCG normalizes (risk of perforation, bleeding, infection)

Referral Criteria to Gynecologic Oncology

• Plateaus across ≥2 weeks
• Rises on weekly measurements
• Persists beyond 6 months

β-hCG Follow-Up Values & Prognosis in GTN

Normal β-hCG Reference Points

Criteria for GTN Diagnosis (Abnormal hCG Patterns)

1. Plateau — hCG level static (< 10% change) over 3 measurements across ≥2 weeks
2. Rise — hCG increases by ≥10% over 3 weekly measurements across ≥2 weeks
3. Persistence — hCG elevated beyond 6 months after evacuation
4. Re-elevation after documented normalization

hCG Levels as a Prognostic Factor (WHO/FIGO Scoring)

FIGO Staging & hCG Correlation

Stage I usually scores low risk; Stage IV always high risk. Stages II–III can be either.

CSF β-hCG: Brain Metastasis

• Plasma : CSF hCG ratio < 60 → suggestive of cerebral metastases
• Useful when brain CT/MRI is normal but CNS involvement is suspected
• Caveat: rapid plasma hCG changes may not be quickly reflected in CSF

Post-Chemotherapy hCG Monitoring (Remission)

• Remission = hCG returning to normal (undetectable) levels after chemotherapy
• High-risk patients: chemotherapy continues until hCG normalizes, then for 6 consecutive additional weeks (consolidation)
• Serial weekly hCG guides response to treatment and detection of drug resistance (plateau or rise during therapy)

GTN After Non-Molar Pregnancy

• Histology is always choriocarcinoma (unlike post-molar GTN which may be invasive mole or choriocarcinoma)
• hCG surveillance follows the same protocol; earlier detection is more challenging as no clear "evacuation" event triggers monitoring
• Consider GTN in any woman with persistent irregular bleeding, hyperemesis, or unexplained elevated hCG after any pregnancy

Risk of Persistent GTN by Mole Type